sulprostone Report issue

Small molecule Experimental
AACT ChEMBL DrugBank Drug Central KEGG MeSH PubChem

Active Ingredient History

Sulprostone is an analogue of prostaglandin E2 (PGE2) that has oxytocic activity in assays of rat kidney cells and tissues. There are four known receptors which mediate various but often different cellular and tissue responses to PGE2: prostaglandin EP1 receptor, prostaglandin EP2 receptor, prostaglandin EP3 receptor, and prostaglandin EP4 receptor. Sulprosotone binds to and activates the prostaglandin EP3 receptor with far greater efficacy than the other PGE2 receptors and also has the advantage of being relatively resistant, compared with PGE2, to becoming metabolically degraded. It is listed as a comparatively weak receptor agonist of the prostaglandin EP1 receptor. In all events, this as well as other potent synthetic EP3 receptor antagonists have the realized or potential ability to promote the beneficial effects of prostaglandin EP3 receptor activation.   Wikipedia

Chemistry

  • SMILES: CS(=O)(=O)NC(=O)CCC/C=C\C[C@H]1C(=O)C[C@@H](O)[C@@H]1/C=C/[C@@H](O)COc1ccccc1
  • InChIKey: UQZVCDCIMBLVNR-TWYODKAFSA-N
  • Mol. Mass: 465.57
  • ALogP: 1.74
  • ChEMBL Molecule:
    sulprostone  
More Chemistry

Pharmacology

Alternative names

16-phenoxy-omega-17,18,19,20-tetranor-pge2 methylsulfonylamide | 16-phenoxytetranor-pge2 methylsulfonylamide | 34.089 pfizer | 5z,13e-18r,11r,12r,15r- dihydroxy-9-oxo-16-phenoxy-17,18,19,20-tetranor- 5,13-prostadienoic acid methylsulfonylamide | cp-34089 | nalador | schering brand of sulprostone | shb 286 | sulproston | sulprostone | zk-57671

Indications (1)

Approved Indications (0)

Experimental Indications - Clinical Trial Phases 1-4 (1)


 

Abortion, Induced (Phase 2)

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue